Even in renal failure patients on PD, introduction of icodextrin has been shown to decrease extra cellular water and improve hemodynamics.
EPIDEMIOLOGY
Heart failure (HF) is a major and growing public health problem in the United States. Overall incidence of congestive heart failure (CHF) approaches 10/1 000 after age of 65 (Framingham Heart Study data) and increases with increasing age. The disorder is the primary reason for 12 to 15 million offi ce visits and 6.5 million hospital days each year.
In 2005 alone, the cost of management of heart failure was $ 27.9 billion in the US. (1) Though multiple clinical trials completed during the past 15 years have unequivocally shown a substantial reduction in mortality for patients with systolic heart failure, large epidemiologic surveys, such as the ongoing Framingham Study, have not documented any meaningful change in overall death rates. 80% of men and 70% of women under age 65 who have CHF will die within 8 years. (1) 
From 1992-2002 deaths from heart failure increased by 35 .3%, while in the same period the overall death rate increased by 7.7%. (2) PATHOPHYSIOLOGY OF HEART FAILURE Various conceptual paradigms have been put forward to explain the clinical syndrome of heart failure. The mechanistic view of heart failure as failure to pump blood at a rate required by the metabolizing tissues, or ability to do so only with an elevated pressure, is only partially correct. Research in the past few decades has highlighted the importance Peritoneal dialysis in congestive heart failure of activation of neurohumoral mechanisms, immune system, ventricular remodeling and development of renal changes, i.e. cardiorenal syndrome in the progression of disease. It is beyond the scope of this review to go over the details. Salient features to understand are that 1) heart failure is a systemic dynamic progressive disease process brought on by the interaction between the heart, kidneys, renin-angiotensin system, sympathetic nervous system, endothelium and immune system through intricate feedback loops, 2) development of cardiorenal syndrome -the spiral of worsening heart failure and kidney failure that leads to diuretic resistance, volume overload and refractory heart failure, and 3) volume overload plays a signifi cant role in pathophysiology of progressive heart failure apart from contributing to symptomatology. (3, 4) 
MANAGEMENT OF VOLUME OVERLOAD IN HEART FAILURE
Insights into these pathophysological mechanisms has changed treatment of heart failure in the last two decades, with the introduction of beta blockers and angiotensin converting enzyme (ACE) inhibitors as the fi rst line of treatment and experimental therapies like anti-tumor necrosis factor (TNF) agent, anti-vasopressin and natriuretic peptides.
It is not within the scope of this paper to go into the details of all the therapies for heart failure. We refer the readers to the American College of Cardiology 2005 guidelines. (5) We'll only discuss problems with management of salt and water excretion in refractory heart failure, newer drugs and the place of peritoneal dialysis. The importance of salt and water management is borne out by the fact that 80% of CHF admissions are for acute decompensation. Most of these patients are admitted for fl uid overload and congestion rather than low perfusion.
Only 5% of patients have low output at admission. (6) Unfortunately, diuretic-based strategies are not always effective in reducing edema. In ADHERE (The Acute Decompensated Heart failure National Registry), 21% of patients admitted for decompensated heart failure were discharged without weight loss or with a gain in weight.
Salt and water excretion is impaired early in patients with congestive heart failure because of the following reasons:
■ Low cardiac output leads to underfi lling and compensatory increase in sodium and water retention in proximal tubules.
■ Activation of Renin Angiotensin Aldosterone System(RAAS) causes sodium retention mediated by Angiotensin II (AT 2) through its action on Angiotensin 1 (AT1) receptor.
■ Release of aldosterone due to RAAS activation impairs distal tubular sodium excretion.
Heart failure is a major and growing health problem. There have been major advances in the understanding of pathophysiology of heart failure as a chronic progressive disorder, which has led to newer therapies. Whatever the etiology, many heart failure patients eventually progress to a refractory stage characterized by worsening renal function and resistance to diuretic therapy with attending severe edema. A logical treatment for this "cardiorenal syndrome" is the use of dialysis, which is effi cient in treating both the hypervolaemia and azotaemia of refractory heart failure. Though all modalities of dialysis have been tried, peritoneal dialysis (PD) is the simplest choice and offers several advantages. It is an already established long-term home-based therapy and does not require complex machinery or hospital resources. PD is associated with preservation of residual renal function, gentle continuous ultrafi ltration, hemodynamic stability, better middle molecule clearance, sodium seiving with maintenance of normonatremia and maybe less infl ammation, especially with newer solutions, compared to hemodialysis. In this paper we discuss the potential advantages of PD in the treatment of heart failure, review available literature and lay some foundation for future research.
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■ Sympathetic activation leads to sodium and water retention indirectly, by activating the RAAS system and by decreasing the glomerular fi ltration rate (GFR) secondary to vasoconstriction.
■ Impairment of GFR mediated by various neurohormonal pathways; vasoactive molecules impair sodium and water excretion.
■ Activation of vasopressin impairs water excretion.
Moreover, heart failure patients with mild to moderate disease have a response that is only one-fourth to one-third of that normally observed with maximally effective doses of loop diuretics. The response in patients with more severe disease is smaller yet. (8) This is due to many of the factors described above, which cause salt and water retention apart from impaired absorption of oral drugs due to gastric congestion and increased proximal tubular absorption, with decreased delivery of fi ltrate to Thick Ascending Limb of Henle (TALH) and distal tubule where the traditional diuretics act.
Apart from failure of therapy, there is concern of increased mortality with use of some classes of diuretics. SOLVD (Studies Of Left Venricular Dysfunction) database demonstrated that, compared with patients not taking any diuretic, the risk of hospitalization or death due to worsening heart failure in patients taking non-potassium sparing diuretics alone was signifi cantly increased (risk ratio -1.31, 95% CI 1.09 to 1.57; p < 0.0004) and this was not observed in patients taking potassium sparing diuretics with or without a non-potassium sparing diuretic. (9) Hence the ongoing search for newer agents in the management of salt and water retention. As such, many of the current standard therapies for heart failure directly or indirectly infl uence sodium and water excretion like beta-blockers, ACE inhibitors, inotropes and aldosterone antagonists. Newer agents like vasopressin receptor antagonists (vaptans), natriuretic peptides and adenosine receptor antagonists being developed for the treatment of heart failure also promote salt and water excretion. Among these, vaptans are the only drugs which are closer to being used in routine clinical practice.
Vasopressin receptor antagonists
Development of vasopressin receptor antagonists was prompted by the realization that levels of arginine vasopressin are elevated in heart failure and are believed to result in 1) myocardial hypertrophy and vasoconstriction mediated by its action on V1a receptor causing vasoconstriction and increasing after load, and 2) water retention and hyponatremia mediated by its action on V2 receptor and thereby increases preload. Early trials have shown that therapy with vaptans signifi cantly reduces weight, corrects hyponatremia, (10) and reduces mortality. (11) These encouraging fi ndings have led to a large multi-center randomised double blind trial EVEREST (The Effi cacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan). In this trial, during a median follow-up of 9.9 months, there was no difference in overall mortality, cardiovascular mortality or hospitalization in the group treated with Tolvaptan as compared to placebo in addition to standard therapy. But Tolvaptan signifi cantly improved secondary end points of day 1 patient-assessed dyspnea, day 1 body weight, and day 7
edema. In patients with hyponatremia, serum sodium levels signifi cantly increased. (12) Ultrafi ltration
The use of ultrafi ltration(UF) for CHF was reported as early as in 1979. (13) However, the need for bulky hemodialysis machines and central venous access made this treatment unpopular. Availability of a new peripheral veno venous hemofi ltration machine (system 100, CHF solutions) has brought this treatment into focus again. Costonza et al. (16) and indicated that patients randomly assigned to receive ultrafi ltration lost more weight and, at 90 days, had a lower rate of rehospitalization.
Incidence of hypotension was similiar in the two groups and ultrafi ltration did not seem to have an adverse effect on the renal function.
Marenzi g et al. (17) studied the effect of ultrafi ltration on hemodynamics in 20 patients with refractory congestive heart failure. All patients underwent ultrafi ltration till Hematocrit increased by 10%. The average
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fl uid removed was 4.88 l + 896ml. They found that mean right atrial, pulmonary artery and wedge pressures decreased and cardiac output and stroke volume increased during the procedure and all the changes persisted up to 24 hours after procedure.
Recently Gura et al. (18) have reported the development and animal trial of a new wearable ultrafi lterable continuous device. The device consists of a hollow fi ber fi lter, a 9 volt battery-operated pulsatile blood pump, a micro pump for heparin infusion, and another micro pump to control ultrafi ltration rate. Blood fl ow used was 65 ml/min and the weight of the device is less than 2.5 lb. Fluid removal rate ranged from 0 to 700 ml/h and averaged 106 ml/h. This treatment modality is still in its infancy. Lots of questions still remain unanswered, such as: 1) Are there mortality and morbidity benefi ts?
2) Who are the patients that are likely to benefi t and at what cost?
3) Are the benefi ts sustained? 4) Does it alter the cardiorenal syndrome or worsen it? 5) Does it alter the pathophysiology of heart failure?
PERITONEAL DIALYSIS
In refractory heart failure the predominant pathophysiology is sodium and fl uid retention, and azotemia due to renal hypoperfusion with inadequate response to traditional medical therapy. A logical treatment for this "cardiorenal syndrome" is the use of dialysis, which is effi cient in treating both the hypervolemia and azotemia of refractory heart failure. have been implicated in the progression of heart failure. The molecular weight of these substances ranges between 500 and 30 000 dalton, which can be removed by PD. Zemel et al. (19) have shown the appearance of TNF alpha, soluble TNF receptor 1 and 2 in the PD effl uent.
Hyponatremia is a marker for poor outcome in heart failure. Among heart failure patients treated with angiotensin-converting enzyme (ACE) inhibitors, diuretics and beta-blockers, even a small decline in serum sodium levels, to 136 mEq/L or less, was associated with more than twice the risk of 60-day mortality and a signifi cant increase in risk of readmission or death within 60 days compared with serum sodium levels greater than 136 mEq/L. (20) In a study of patients with end-stage heart failure, Licata G et al., (21) attempted to isolate the effect of an increase in serum sodium on clinical outcome. They randomized 107 patients with refractory heart failure to receive an IV infusion of furosemide plus hypertonic 3% saline solution or an IV bolus of furosemide twice a day without hypertonic saline. Survival over a mean follow-up of 31 months was 55% in the group that received hypertonic saline compared with 13% in those that did not receive hypertonic saline (P < .001). This suggests that normalization of a low serum sodium by sodium seiving may be another potential mechanism of benefi t for PD.
Renal insuffi ciency signifi cantly increases the risk of death and thus is an important prognostic indicator in heart failure patients. Hillege et al. (22) reported in the Second Prospective Randomized Study of Ibopamine on Mortality and Effi cacy (PRIME-2) that patients with GFRs in the lowest quartile (< 44 mL/minute) had almost a three times higher risk of mortality than those in the highest quartile (GFR > 76; relative risk 2.85, P < .0001). Impaired renal function was a stronger predictor of death in these patients with heart failure than a low ejection fraction.
Forman et al. (23) found that heart failure patients whose renal function worsened while in the hospital had longer stays, incurred higher hospital costs, were more likely to die in the hospital and, if they survived the hospitalization, were more likely to be readmitted. It is not very clear whether this is an association because patients with renal failure are more likely to have refractory heart failure or if preserved renal function protects from worsening heart failure due to less infl ammatory activation.
PD again has an advantage by preserving residual renal function.
In 1949, Schneierson (24) published the fi rst case report using PD as a successful therapy in a patient with severe CHF. Since then there have been multiple case reports and small series. Review of use of PD in CHF can be divided into three periods -intermittent PD(IPD), continuous PD and newer soultions. During these three phases, not only the technology of PD has changed, but also treatment of CHF has changed.
Intermittent PD
In the 1960s many cases of acute CHF treated by PD have been reported, in total about 56 such patients. In summary these reports demonstrated fl uid removal rate of 67-568ml/hour with improvement in symptoms in most of the patients. Fluid removal was associated with an improvement in plasma volume (25) and hyponatremia. The patient underwent a total of 8 treatments over a period of 2 years and eventually died in a car accident. But later reports were not so optimistic. Shapira et al. (29) reported repeated intermittent PD in 10 patients with refractory CHF. Though all patients showed improvement in symptomatology, sodium levels, urine output and diuretic responsiveness, 50% of the patients died 99 to 354 days after their fi rst dialysis. 90% of their patients also had gram negative bacteria cultured from their PD fl uid but none of the patients developed peritonitis. Another major limitation of this therapy was requirement of frequent hospitalization for the procedure.
Continuous PD
Despite the initial disappointment with IPD in the long-term management of heart failure, it was clear that Continuous PD (CAPD), because of its continuous nature, will be more appropriate. There are multiple case series on the use of CAPD and we summarise the major trials in the Table I. (NO TABLE SUPPLIED) As we can see from the table, all patients show symptomatic improvement while on PD. Hospitalisation rate was decreased in all studies except the one reported by Rubin et al. (33) In their study patients were hospitalized as often for PD-related problems as for cardiac problems. Peritonitis rates were high in the earlier studies, which is not the problem with the newer connecting devices and automated devices.
Though all patients showed symptomatic improvement, mortality remained high. It is not clear whether better volume management will translate to delay in progression of heart failure. There was no correlation between functional improvement and LV function as measured by left ventricular ejection fraction (LVEF).
(31) But Stegmayr et al. (35) have shown reduction in CT index and Gotloib et al. (39) in their study found an improvement in the cardiac work index. Long-term follow-up studies are required to see the effect on progression.
Though mortality was high in most of the studies, survival seems to be improving in the recent trials. Stegmayr et al. (35) studied patients with expected survival of 1 month and showed a signifi cant prolonged survival from 1 month up to 1 year. In the study by Gotloib et al. (39) they found a 1-year mortality rate of 10%, which was signifi cantly less than the 80% expected based on their charles comorbidity index. It is diffi cult to interpret these mortality data because none of these trials compared PD to standard care of therapy. It will be not be possible to do such a trial in patients with refractory heart failure and, for that matter, cardiac transplantation has never been compared either. It is also diffi cult to interpret whether this improvement is because of PD or overall improved management and survival in CHF patients with newer therapies.
It is also interesting to note that in the trial by Ryckelynck et al. (36) two patients who were earlier rejected for cardiac transplant were found to be fi t and got transplanted after starting PD. In the trial by Konig et al. (34) three patients had cardiac transplantation after starting PD. PD could be afforded to patients waiting for cardiac transplant as bridge therapy.
